At a glance
- Originator Tokyo University of Science
- Class Antidementias; Neuroprotectants
- Mechanism of Action Cholecystokinin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 22 Jan 1997 No-Development-Reported for Cognition disorders in Japan (Unknown route)